Skip to main content
Erschienen in: Neuroradiology 7/2021

25.11.2020 | Diagnostic Neuroradiology

Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score

verfasst von: Francisco Carlos Pérez-Miralles, Jordi Río, Deborah Pareto, Àngela Vidal-Jordana, Cristina Auger, Georgina Arrambide, Joaquín Castilló, Mar Tintoré, Àlex Rovira, Xavier Montalban, Jaume Sastre-Garriga

Erschienen in: Neuroradiology | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Brain volume changes (BVC) on therapy in MS are being considered as predictor for treatment response at an individual level. We ought to assess whether adding BVC as a factor to monitor interferon-beta response improves the predictive ability of the (no) evidence of disease activity (EDA-3) and Río score (RS-3) criteria for confirmed disability progression in a historical cohort.

Methods

One hundred one patients from an observational cohort treated with interferon-beta were assessed for different cutoff points of BVC (ranged 0.2–1.2%), presence of active lesions (≥ 1 for EDA/≥ 3 for RS), relapses, and 6-month confirmed disability progression (CDP), measured by the Expanded Disability Status Scale, after 1 year. Sensitivity, specificity, and positive and negative predictive values for predicting confirmed disability progression at 4 years in original EDA (EDA-3) and RS (RS-3) as well as EDA and RS including BVC (EDA-4 and RS-4) were compared.

Results

Adding BVC to EDA slightly increased sensitivity, but not specificity or predictive values, nor the OR for predicting CDP; only EDA-3 showed a trend for predicting CDP (OR 3.701, p = 0.050). Adding BVC to RS-3 (defined as ≥ 2 criteria) helped to improve sensitivity and negative predictive value, and increased OR for predicting CDP using a cutoff of ≤ − 0.86% (RS-3 OR 23.528, p < 0.001; RS-4 for all cutoffs ranged from 15.06 to 32, p < 0.001). RS-4 showed areas under the curve larger than RS-3 for prediction of disability at 4 years.

Conclusion

Addition of BVC to RS improves its prediction of response to interferon-beta.
Literatur
3.
Zurück zum Zitat Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://​doi.​org/​10.​1016/​S1474-4422(17)30470-2CrossRefPubMed
13.
Zurück zum Zitat Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ (2005) Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 65:633–635. https://doi.org/10.1212/01.wnl.0000173061.12776.1fCrossRefPubMed Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ (2005) Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 65:633–635. https://​doi.​org/​10.​1212/​01.​wnl.​0000173061.​12776.​1fCrossRefPubMed
18.
Zurück zum Zitat Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, de Stefano N, and the MAGNIMS Study Group (2019) Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92:180–192. https://doi.org/10.1212/WNL.0000000000006810CrossRefPubMedPubMedCentral Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, de Stefano N, and the MAGNIMS Study Group (2019) Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92:180–192. https://​doi.​org/​10.​1212/​WNL.​0000000000006810​CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, de Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BMJ, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H, on behalf of the MAGNIMS Study Group (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091. https://doi.org/10.1136/jnnp-2012-304094CrossRefPubMed Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, de Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BMJ, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H, on behalf of the MAGNIMS Study Group (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091. https://​doi.​org/​10.​1136/​jnnp-2012-304094CrossRefPubMed
24.
25.
Zurück zum Zitat Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260. https://doi.org/10.1016/S1474-4422(09)70021-3CrossRefPubMed Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260. https://​doi.​org/​10.​1016/​S1474-4422(09)70021-3CrossRefPubMed
29.
Zurück zum Zitat Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, Arévalo MJ, Castilló J, Rovira A, Montalban X (2013) Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 19:1175–1181. https://doi.org/10.1177/1352458512473190CrossRefPubMed Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, Arévalo MJ, Castilló J, Rovira A, Montalban X (2013) Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 19:1175–1181. https://​doi.​org/​10.​1177/​1352458512473190​CrossRefPubMed
Metadaten
Titel
Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score
verfasst von
Francisco Carlos Pérez-Miralles
Jordi Río
Deborah Pareto
Àngela Vidal-Jordana
Cristina Auger
Georgina Arrambide
Joaquín Castilló
Mar Tintoré
Àlex Rovira
Xavier Montalban
Jaume Sastre-Garriga
Publikationsdatum
25.11.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Neuroradiology / Ausgabe 7/2021
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-020-02604-8

Weitere Artikel der Ausgabe 7/2021

Neuroradiology 7/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.